Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Issue 1 (2nd January 2022)

• Record Type: Journal Article
• Authors: Wharton, Sean; Davies, Melanie; Dicker, Dror; Lingvay, Ildiko; Mosenzon, Ofri; Rubino, Domenica M.; Pedersen, Sue D.
• Is Part Of: Postgraduate medicine. Volume 134:Issue 1(2022)
• Page Start: 14
• Page End: 19
• Publication Date: 2022-01-02
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Medicine; Periodicals; 610.5
• DOI: 10.1080/00325481.2021.2002616
• Languages: English
• ISSNs: 0032-5481

Abstract

Abstract: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established in clinical practice for the treatment of type 2 diabetes, and are approved and recommended for weight management in overweight or obesity. Gastrointestinal side effects are well known as the most common adverse effects of these agents and represent a potential barrier for use, particularly at higher doses. Drawing on both published evidence and our collective clinical experience, we aim to guide practitioners through managing these side effects with a view to optimizing therapeutic outcomes with GLP-1RAs. Abstract :